Condition: Recurrent Hepatocellular Carcinoma · Lenvatinib · Local Therapy · Sponsor: Sun Yat-sen University
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.
This description comes directly from the study's public registry record.
Qunfang Zhou · 86 19868000115 · zhouqun988509@163.com
Feng Duan · 86 13910984586 · duanfeng@vip.sina.com
Always discuss trial participation with your own doctor first.
| Chinese PLA General hospital | Beijing, None Selected, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06609850